Intellia Therapeutics (NASDAQ:NTLA) CEO John Leonard Sells 9,000 Shares of Company Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John Leonard sold 9,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the transaction, the chief executive officer directly owned 1,138,064 shares in the company, valued at $13,645,387.36. This represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Intellia Therapeutics Trading Up 1.7%

NASDAQ:NTLA opened at $11.86 on Wednesday. Intellia Therapeutics, Inc. has a 1 year low of $7.95 and a 1 year high of $18.48. The stock has a fifty day moving average price of $12.20 and a two-hundred day moving average price of $13.06.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. During the same period in the previous year, the firm earned ($0.98) EPS. The business’s revenue was down 46.4% on a year-over-year basis. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

Several large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Intellia Therapeutics in the second quarter valued at about $260,721,000. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Intellia Therapeutics by 24.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,605,623 shares of the company’s stock valued at $43,484,000 after purchasing an additional 708,094 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Intellia Therapeutics by 20.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,318,110 shares of the company’s stock worth $29,709,000 after purchasing an additional 386,261 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Intellia Therapeutics during the 1st quarter worth approximately $17,913,000. Finally, Bank of America Corp DE increased its stake in shares of Intellia Therapeutics by 11.2% during the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after purchasing an additional 139,325 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wall Street Zen cut shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Wolfe Research lowered shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research report on Wednesday, July 15th. Barclays started coverage on shares of Intellia Therapeutics in a report on Tuesday, October 6th. They issued an “underweight” rating and a $8.00 target price for the company. Wedbush increased their target price on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $20.57.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.